381 Participants Needed

ND0612 for Parkinson's Disease

(BouNDless Trial)

Recruiting at 121 trial locations
HE
ET
Overseen ByEran Tavor
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: NeuroDerm Ltd.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.

Research Team

OR

Olivier Rascol, MD, PhD

Principal Investigator

Toulouse University Hospital, France

AJ

Alberto Espay, MD

Principal Investigator

University of Cincinnati OH, USA

Eligibility Criteria

This trial is for adults aged 30 or older with Parkinson's Disease who experience at least 2 hours of 'OFF' time daily, despite taking levodopa. They should not have had neurosurgery for PD, severe skin conditions, disabling dyskinesias, or used certain PD medications recently.

Inclusion Criteria

You have been diagnosed with Parkinson's disease according to the United Kingdom Brain Bank Criteria.
I experience more than 2.5 hours of symptom worsening during the day.
I take 4 or more daily doses of levodopa, totaling 400mg or more.
See 7 more

Exclusion Criteria

My condition is not typical Parkinson's but a variant or caused by another condition.
I haven't used apomorphine injections, sublingual apomorphine, or inhaled levodopa in the last 4 weeks.
I am using a duodenal levodopa or apomorphine infusion.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Oral IR-LD/CD Adjustment

Participants undergo an open-label oral IR-LD/CD adjustment period

4-6 weeks

ND0612 Conversion

Participants undergo an open-label ND0612 conversion period

4-6 weeks

Maintenance

Randomized double-blind, double-dummy active-controlled maintenance period

12 weeks

Open-label Extension (optional)

Participants may opt into continuation of treatment long-term

up to 54 months

Safety Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Carbidopa and Levodopa 25mg/100mg
  • ND0612 Solution
  • Placebo for Carbidopa and Levodopa 25mg/100mg
  • Placebo for ND0612 Solution
Trial Overview The study compares ND0612, a continuous subcutaneous infusion solution, to the standard oral immediate-release Levodopa/Carbidopa (IR-LD/CD). Participants will first adjust to IR-LD/CD before switching to ND0612 or placebo and then may enter an open-label extension.
Participant Groups
5Treatment groups
Experimental Treatment
Active Control
Group I: Oral IR-LD/CD AdjustmentExperimental Treatment1 Intervention
Active IR-LD/CD (white capsules). Open-label Treatment in Run-in 1 for 4-6 weeks.
Group II: Open-Label ExtensionExperimental Treatment1 Intervention
ND0612 continuous SC infusion + Standard of care LD/dopa-decarboxylase inhibitor. Open-label Treatment in Extension for up to 54 months.
Group III: ND0612 GroupExperimental Treatment3 Interventions
ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules) + Placebo IR-LD/CD (white capsules). Randomized DBDD Maintenance Treatment for 12 weeks.
Group IV: ND0612 ConversionExperimental Treatment2 Interventions
ND0612 continuous SC infusion + Active IR-LD/CD (grey capsules). Open-label Treatment in Run-in 2 for 4-6 weeks.
Group V: IR-LD/CD GroupActive Control3 Interventions
Placebo for ND0612 continuous SC infusion + Placebo IR-LD/CD (grey capsules) + Active IR-LD/CD (white capsules). Randomized DBDD Maintenance Treatment for 12 weeks.

Find a Clinic Near You

Who Is Running the Clinical Trial?

NeuroDerm Ltd.

Lead Sponsor

Trials
14
Recruited
840+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security